MovDisordV3, PascalFrancis, Corpus, bibRecord, 001A10

Electrophysiological deterioration over time in patients with huntington's disease

Identifieur interne : 001A10 ( PascalFrancis/Corpus ); précédent : 001A09; suivant : 001A11

Electrophysiological deterioration over time in patients with huntington's disease

Auteurs : Jean-Pascal Lefaucheur ; Isabelle Menard-Lefaucheur ; Patrick Maison ; Sophie Baudic ; Pierre Cesaro ; Marc Peschanski ; Anne-Catherine Bachoud-Levi

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0518086

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Chorée Huntington, Détérioration, Homme, Programme, Réflexe palpébral, Potentiel évoqué somatosensoriel, Période muette, Stimulation magnétique transcrânienne.

English descriptors

KwdEn :
- Deterioration, Human, Huntington disease, Nervous system diseases, Palpebral reflex, Program, Silent period, Somatosensory evoked potential, Transcranial magnetic stimulation.

Abstract

In recent studies aimed at assessing the effects of original therapeutic strategies applied to patients with Huntington's disease (HD), we observed informative changes in electrophysiological results that recovered normal values in coherence with clinical improvement. However, longitudinal studies were lacking for determining whether electrophysiological test results evolve in parallel with clinical markers of the natural course of the disease and could consequently provide objective quantifiable markers of disease progression. For this purpose, electrophysiological testing was performed annually in a cohort of 20 patients with HD over a 2-year period (three examinations). The study included the recording of sympathetic skin responses and blink reflexes (BRs) to supraorbital nerve stimulation, long latency reflexes (LLRs) and somatosensory evoked potentials (SEPs) to median nerve stimulation, and cortical silent periods (CSPs) to transcranial magnetic stimulation. Clinical evaluation was based on the Total Functional Capacity scale (TFC) and the Motor part of the Unified Huntington's Disease Rating Scale (UHDRS). A significant deterioration with time was found for BR latency, LLR presence, various SEP parameters (parietal N20 peak amplitude and frontal N30 presence) and CSP duration. Attenuation of the N20 peak and CSP shortening correlated with functional decline, as assessed by the TFC score, whereas delayed BR and LLR abolition correlated with UHDRS Motor score deterioration. This study shows that several electrophysiological parameters are closely associated with dysfunction of various neural circuits in HD and could be useful markers of disease progression.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Electrophysiological deterioration over time in patients with huntington's disease`
A11	`01`	`1`		`@1 LEFAUCHEUR (Jean-Pascal)`
A11	`02`	`1`		`@1 MENARD-LEFAUCHEUR (Isabelle)`
A11	`03`	`1`		`@1 MAISON (Patrick)`
A11	`04`	`1`		`@1 BAUDIC (Sophie)`
A11	`05`	`1`		`@1 CESARO (Pierre)`
A11	`06`	`1`		`@1 PESCHANSKI (Marc)`
A11	`07`	`1`		`@1 BACHOUD-LEVI (Anne-Catherine)`
A14	`01`			`@1 Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, AP-HP @2 Créteil @3 FRA @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 INSERM U421, IM3, Faculté de Médecine @2 Créteil @3 FRA @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A14	`03`			`@1 Service de Pharmacologie Clinique, Hôpital Henri Mondor, AP-HP @2 Créteil @3 FRA @Z 3 aut.`
A14	`04`			`@1 Service de Neurologie, Hôpital Henri Mondor, AP-HP @2 Créteil @3 FRA @Z 5 aut. @Z 7 aut.`
A20				`@1 1350-1354`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000158780860080`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 32 ref.`
A47	`01`	`1`		`@0 06-0518086`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 In recent studies aimed at assessing the effects of original therapeutic strategies applied to patients with Huntington's disease (HD), we observed informative changes in electrophysiological results that recovered normal values in coherence with clinical improvement. However, longitudinal studies were lacking for determining whether electrophysiological test results evolve in parallel with clinical markers of the natural course of the disease and could consequently provide objective quantifiable markers of disease progression. For this purpose, electrophysiological testing was performed annually in a cohort of 20 patients with HD over a 2-year period (three examinations). The study included the recording of sympathetic skin responses and blink reflexes (BRs) to supraorbital nerve stimulation, long latency reflexes (LLRs) and somatosensory evoked potentials (SEPs) to median nerve stimulation, and cortical silent periods (CSPs) to transcranial magnetic stimulation. Clinical evaluation was based on the Total Functional Capacity scale (TFC) and the Motor part of the Unified Huntington's Disease Rating Scale (UHDRS). A significant deterioration with time was found for BR latency, LLR presence, various SEP parameters (parietal N20 peak amplitude and frontal N30 presence) and CSP duration. Attenuation of the N20 peak and CSP shortening correlated with functional decline, as assessed by the TFC score, whereas delayed BR and LLR abolition correlated with UHDRS Motor score deterioration. This study shows that several electrophysiological parameters are closely associated with dysfunction of various neural circuits in HD and could be useful markers of disease progression.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Chorée Huntington @5 02`
C03	`02`	`X`	`ENG`	`@0 Huntington disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Corea Huntington @5 02`
C03	`03`	`X`	`FRE`	`@0 Détérioration @5 09`
C03	`03`	`X`	`ENG`	`@0 Deterioration @5 09`
C03	`03`	`X`	`SPA`	`@0 Deterioración @5 09`
C03	`04`	`X`	`FRE`	`@0 Homme @5 10`
C03	`04`	`X`	`ENG`	`@0 Human @5 10`
C03	`04`	`X`	`SPA`	`@0 Hombre @5 10`
C03	`05`	`X`	`FRE`	`@0 Programme @5 11`
C03	`05`	`X`	`ENG`	`@0 Program @5 11`
C03	`05`	`X`	`SPA`	`@0 Programa @5 11`
C03	`06`	`X`	`FRE`	`@0 Réflexe palpébral @5 12`
C03	`06`	`X`	`ENG`	`@0 Palpebral reflex @5 12`
C03	`06`	`X`	`SPA`	`@0 Reflejo palpebral @5 12`
C03	`07`	`X`	`FRE`	`@0 Potentiel évoqué somatosensoriel @5 13`
C03	`07`	`X`	`ENG`	`@0 Somatosensory evoked potential @5 13`
C03	`07`	`X`	`SPA`	`@0 Potencial evocado somatosensorial @5 13`
C03	`08`	`X`	`FRE`	`@0 Période muette @4 CD @5 96`
C03	`08`	`X`	`ENG`	`@0 Silent period @4 CD @5 96`
C03	`09`	`X`	`FRE`	`@0 Stimulation magnétique transcrânienne @4 CD @5 97`
C03	`09`	`X`	`ENG`	`@0 Transcranial magnetic stimulation @4 CD @5 97`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie héréditaire @5 40`
C07	`04`	`X`	`ENG`	`@0 Genetic disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad hereditaria @5 40`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
C07	`06`	`X`	`FRE`	`@0 Electrophysiologie @5 42`
C07	`06`	`X`	`ENG`	`@0 Electrophysiology @5 42`
C07	`06`	`X`	`SPA`	`@0 Electrofisiología @5 42`
N21				`@1 338`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0518086 INIST
ET :	Electrophysiological deterioration over time in patients with huntington's disease
AU :	LEFAUCHEUR (Jean-Pascal); MENARD-LEFAUCHEUR (Isabelle); MAISON (Patrick); BAUDIC (Sophie); CESARO (Pierre); PESCHANSKI (Marc); BACHOUD-LEVI (Anne-Catherine)
AF :	Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, AP-HP/Créteil/France (1 aut., 2 aut.); INSERM U421, IM3, Faculté de Médecine/Créteil/France (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut.); Service de Pharmacologie Clinique, Hôpital Henri Mondor, AP-HP/Créteil/France (3 aut.); Service de Neurologie, Hôpital Henri Mondor, AP-HP/Créteil/France (5 aut., 7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 9; Pp. 1350-1354; Bibl. 32 ref.
LA :	Anglais
EA :	In recent studies aimed at assessing the effects of original therapeutic strategies applied to patients with Huntington's disease (HD), we observed informative changes in electrophysiological results that recovered normal values in coherence with clinical improvement. However, longitudinal studies were lacking for determining whether electrophysiological test results evolve in parallel with clinical markers of the natural course of the disease and could consequently provide objective quantifiable markers of disease progression. For this purpose, electrophysiological testing was performed annually in a cohort of 20 patients with HD over a 2-year period (three examinations). The study included the recording of sympathetic skin responses and blink reflexes (BRs) to supraorbital nerve stimulation, long latency reflexes (LLRs) and somatosensory evoked potentials (SEPs) to median nerve stimulation, and cortical silent periods (CSPs) to transcranial magnetic stimulation. Clinical evaluation was based on the Total Functional Capacity scale (TFC) and the Motor part of the Unified Huntington's Disease Rating Scale (UHDRS). A significant deterioration with time was found for BR latency, LLR presence, various SEP parameters (parietal N20 peak amplitude and frontal N30 presence) and CSP duration. Attenuation of the N20 peak and CSP shortening correlated with functional decline, as assessed by the TFC score, whereas delayed BR and LLR abolition correlated with UHDRS Motor score deterioration. This study shows that several electrophysiological parameters are closely associated with dysfunction of various neural circuits in HD and could be useful markers of disease progression.
CC :	002B17; 002B17G; 002B17F
FD :	Système nerveux pathologie; Chorée Huntington; Détérioration; Homme; Programme; Réflexe palpébral; Potentiel évoqué somatosensoriel; Période muette; Stimulation magnétique transcrânienne
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Maladie héréditaire; Système nerveux central pathologie; Electrophysiologie
ED :	Nervous system diseases; Huntington disease; Deterioration; Human; Program; Palpebral reflex; Somatosensory evoked potential; Silent period; Transcranial magnetic stimulation
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Genetic disease; Central nervous system disease; Electrophysiology
SD :	Sistema nervioso patología; Corea Huntington; Deterioración; Hombre; Programa; Reflejo palpebral; Potencial evocado somatosensorial
LO :	INIST-20953.354000158780860080
ID :	06-0518086

Links to Exploration step

Pascal:06-0518086

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Electrophysiological deterioration over time in patients with huntington's disease</title>
<author><name sortKey="Lefaucheur, Jean Pascal" sort="Lefaucheur, Jean Pascal" uniqKey="Lefaucheur J" first="Jean-Pascal" last="Lefaucheur">Jean-Pascal Lefaucheur</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menard Lefaucheur, Isabelle" sort="Menard Lefaucheur, Isabelle" uniqKey="Menard Lefaucheur I" first="Isabelle" last="Menard-Lefaucheur">Isabelle Menard-Lefaucheur</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maison, Patrick" sort="Maison, Patrick" uniqKey="Maison P" first="Patrick" last="Maison">Patrick Maison</name>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Service de Pharmacologie Clinique, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baudic, Sophie" sort="Baudic, Sophie" uniqKey="Baudic S" first="Sophie" last="Baudic">Sophie Baudic</name>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Service de Neurologie, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peschanski, Marc" sort="Peschanski, Marc" uniqKey="Peschanski M" first="Marc" last="Peschanski">Marc Peschanski</name>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bachoud Levi, Anne Catherine" sort="Bachoud Levi, Anne Catherine" uniqKey="Bachoud Levi A" first="Anne-Catherine" last="Bachoud-Levi">Anne-Catherine Bachoud-Levi</name>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Service de Neurologie, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0518086</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0518086 INIST</idno>
<idno type="RBID">Pascal:06-0518086</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A10</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Electrophysiological deterioration over time in patients with huntington's disease</title>
<author><name sortKey="Lefaucheur, Jean Pascal" sort="Lefaucheur, Jean Pascal" uniqKey="Lefaucheur J" first="Jean-Pascal" last="Lefaucheur">Jean-Pascal Lefaucheur</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menard Lefaucheur, Isabelle" sort="Menard Lefaucheur, Isabelle" uniqKey="Menard Lefaucheur I" first="Isabelle" last="Menard-Lefaucheur">Isabelle Menard-Lefaucheur</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maison, Patrick" sort="Maison, Patrick" uniqKey="Maison P" first="Patrick" last="Maison">Patrick Maison</name>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Service de Pharmacologie Clinique, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baudic, Sophie" sort="Baudic, Sophie" uniqKey="Baudic S" first="Sophie" last="Baudic">Sophie Baudic</name>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Service de Neurologie, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peschanski, Marc" sort="Peschanski, Marc" uniqKey="Peschanski M" first="Marc" last="Peschanski">Marc Peschanski</name>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bachoud Levi, Anne Catherine" sort="Bachoud Levi, Anne Catherine" uniqKey="Bachoud Levi A" first="Anne-Catherine" last="Bachoud-Levi">Anne-Catherine Bachoud-Levi</name>
<affiliation><inist:fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Service de Neurologie, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Deterioration</term>
<term>Human</term>
<term>Huntington disease</term>
<term>Nervous system diseases</term>
<term>Palpebral reflex</term>
<term>Program</term>
<term>Silent period</term>
<term>Somatosensory evoked potential</term>
<term>Transcranial magnetic stimulation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Chorée Huntington</term>
<term>Détérioration</term>
<term>Homme</term>
<term>Programme</term>
<term>Réflexe palpébral</term>
<term>Potentiel évoqué somatosensoriel</term>
<term>Période muette</term>
<term>Stimulation magnétique transcrânienne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In recent studies aimed at assessing the effects of original therapeutic strategies applied to patients with Huntington's disease (HD), we observed informative changes in electrophysiological results that recovered normal values in coherence with clinical improvement. However, longitudinal studies were lacking for determining whether electrophysiological test results evolve in parallel with clinical markers of the natural course of the disease and could consequently provide objective quantifiable markers of disease progression. For this purpose, electrophysiological testing was performed annually in a cohort of 20 patients with HD over a 2-year period (three examinations). The study included the recording of sympathetic skin responses and blink reflexes (BRs) to supraorbital nerve stimulation, long latency reflexes (LLRs) and somatosensory evoked potentials (SEPs) to median nerve stimulation, and cortical silent periods (CSPs) to transcranial magnetic stimulation. Clinical evaluation was based on the Total Functional Capacity scale (TFC) and the Motor part of the Unified Huntington's Disease Rating Scale (UHDRS). A significant deterioration with time was found for BR latency, LLR presence, various SEP parameters (parietal N20 peak amplitude and frontal N30 presence) and CSP duration. Attenuation of the N20 peak and CSP shortening correlated with functional decline, as assessed by the TFC score, whereas delayed BR and LLR abolition correlated with UHDRS Motor score deterioration. This study shows that several electrophysiological parameters are closely associated with dysfunction of various neural circuits in HD and could be useful markers of disease progression.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Electrophysiological deterioration over time in patients with huntington's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LEFAUCHEUR (Jean-Pascal)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MENARD-LEFAUCHEUR (Isabelle)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MAISON (Patrick)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BAUDIC (Sophie)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CESARO (Pierre)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>PESCHANSKI (Marc)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>BACHOUD-LEVI (Anne-Catherine)</s1>
</fA11>
<fA14 i1="01"><s1>Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>INSERM U421, IM3, Faculté de Médecine</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Service de Pharmacologie Clinique, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Service de Neurologie, Hôpital Henri Mondor, AP-HP</s1>
<s2>Créteil</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>1350-1354</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000158780860080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>32 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0518086</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In recent studies aimed at assessing the effects of original therapeutic strategies applied to patients with Huntington's disease (HD), we observed informative changes in electrophysiological results that recovered normal values in coherence with clinical improvement. However, longitudinal studies were lacking for determining whether electrophysiological test results evolve in parallel with clinical markers of the natural course of the disease and could consequently provide objective quantifiable markers of disease progression. For this purpose, electrophysiological testing was performed annually in a cohort of 20 patients with HD over a 2-year period (three examinations). The study included the recording of sympathetic skin responses and blink reflexes (BRs) to supraorbital nerve stimulation, long latency reflexes (LLRs) and somatosensory evoked potentials (SEPs) to median nerve stimulation, and cortical silent periods (CSPs) to transcranial magnetic stimulation. Clinical evaluation was based on the Total Functional Capacity scale (TFC) and the Motor part of the Unified Huntington's Disease Rating Scale (UHDRS). A significant deterioration with time was found for BR latency, LLR presence, various SEP parameters (parietal N20 peak amplitude and frontal N30 presence) and CSP duration. Attenuation of the N20 peak and CSP shortening correlated with functional decline, as assessed by the TFC score, whereas delayed BR and LLR abolition correlated with UHDRS Motor score deterioration. This study shows that several electrophysiological parameters are closely associated with dysfunction of various neural circuits in HD and could be useful markers of disease progression.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Chorée Huntington</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Huntington disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Corea Huntington</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Détérioration</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Deterioration</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Deterioración</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Homme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Human</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Programme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Program</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Programa</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Réflexe palpébral</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Palpebral reflex</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Reflejo palpebral</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Potentiel évoqué somatosensoriel</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Somatosensory evoked potential</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Potencial evocado somatosensorial</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Période muette</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Silent period</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Stimulation magnétique transcrânienne</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Transcranial magnetic stimulation</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie héréditaire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Genetic disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Electrophysiologie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Electrophysiology</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Electrofisiología</s0>
<s5>42</s5>
</fC07>
<fN21><s1>338</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0518086 INIST</NO>
<ET>Electrophysiological deterioration over time in patients with huntington's disease</ET>
<AU>LEFAUCHEUR (Jean-Pascal); MENARD-LEFAUCHEUR (Isabelle); MAISON (Patrick); BAUDIC (Sophie); CESARO (Pierre); PESCHANSKI (Marc); BACHOUD-LEVI (Anne-Catherine)</AU>
<AF>Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, AP-HP/Créteil/France (1 aut., 2 aut.); INSERM U421, IM3, Faculté de Médecine/Créteil/France (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut.); Service de Pharmacologie Clinique, Hôpital Henri Mondor, AP-HP/Créteil/France (3 aut.); Service de Neurologie, Hôpital Henri Mondor, AP-HP/Créteil/France (5 aut., 7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 9; Pp. 1350-1354; Bibl. 32 ref.</SO>
<LA>Anglais</LA>
<EA>In recent studies aimed at assessing the effects of original therapeutic strategies applied to patients with Huntington's disease (HD), we observed informative changes in electrophysiological results that recovered normal values in coherence with clinical improvement. However, longitudinal studies were lacking for determining whether electrophysiological test results evolve in parallel with clinical markers of the natural course of the disease and could consequently provide objective quantifiable markers of disease progression. For this purpose, electrophysiological testing was performed annually in a cohort of 20 patients with HD over a 2-year period (three examinations). The study included the recording of sympathetic skin responses and blink reflexes (BRs) to supraorbital nerve stimulation, long latency reflexes (LLRs) and somatosensory evoked potentials (SEPs) to median nerve stimulation, and cortical silent periods (CSPs) to transcranial magnetic stimulation. Clinical evaluation was based on the Total Functional Capacity scale (TFC) and the Motor part of the Unified Huntington's Disease Rating Scale (UHDRS). A significant deterioration with time was found for BR latency, LLR presence, various SEP parameters (parietal N20 peak amplitude and frontal N30 presence) and CSP duration. Attenuation of the N20 peak and CSP shortening correlated with functional decline, as assessed by the TFC score, whereas delayed BR and LLR abolition correlated with UHDRS Motor score deterioration. This study shows that several electrophysiological parameters are closely associated with dysfunction of various neural circuits in HD and could be useful markers of disease progression.</EA>
<CC>002B17; 002B17G; 002B17F</CC>
<FD>Système nerveux pathologie; Chorée Huntington; Détérioration; Homme; Programme; Réflexe palpébral; Potentiel évoqué somatosensoriel; Période muette; Stimulation magnétique transcrânienne</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Maladie héréditaire; Système nerveux central pathologie; Electrophysiologie</FG>
<ED>Nervous system diseases; Huntington disease; Deterioration; Human; Program; Palpebral reflex; Somatosensory evoked potential; Silent period; Transcranial magnetic stimulation</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Genetic disease; Central nervous system disease; Electrophysiology</EG>
<SD>Sistema nervioso patología; Corea Huntington; Deterioración; Hombre; Programa; Reflejo palpebral; Potencial evocado somatosensorial</SD>
<LO>INIST-20953.354000158780860080</LO>
<ID>06-0518086</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A10 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A10 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0518086
   |texte=   Electrophysiological deterioration over time in patients with huntington's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Electrophysiological deterioration over time in patients with huntington's disease

Electrophysiological deterioration over time in patients with huntington's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri